Stockhub

Oryzon Genomics S.A.

Revision as of 06:34, 3 September 2022 by 95.149.241.133 (talk) (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=Oryzon_Genomics_S.A.&oldid=61677"